A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

Standard cytotoxic treatments for neuroendocrine tumours have been associated with limited activity and remarkable toxicity. A phase II study was designed to evaluate the efficacy, safety and pharmacodynamics of temsirolimus in patients with advanced neuroendocrine carcinoma (NEC). Thirty-seven pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Duran, I, Kortmansky, J, Singh, D, Hirte, H, Kocha, W, Goss, G, Le, L, Oza, A, Nicklee, T, Ho, J, Birle, D, Pond, G R, Arboine, D, Dancey, J, Aviel-Ronen, S, Tsao, M-S, Hedley, D, Siu, L L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360568/
https://www.ncbi.nlm.nih.gov/pubmed/17031397
http://dx.doi.org/10.1038/sj.bjc.6603419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360568/
https://www.ncbi.nlm.nih.gov/pubmed/17031397
http://dx.doi.org/10.1038/sj.bjc.6603419

Ejemplares similares